Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide

Raffaele De Caterina; Walter Ageno; Giuseppe Boriani; Paolo Colonna; Angelo Ghirarduzzi; Giuseppe Patti; Roberta Rossini; Andrea Rubboli; Piercarla Schinco; Giancarlo Agnelli

doi:10.1007/s12325-017-0488-9

Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide

Raffaele De Caterina, Walter Ageno, Giuseppe Boriani, Paolo Colonna, Angelo Ghirarduzzi, Giuseppe Patti, Roberta Rossini, Andrea Rubboli, Piercarla Schinco, Giancarlo Agnelli

Research output: Contribution to journal › Article › peer-review

Abstract

Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials with the vitamin K antagonist warfarin. Edoxaban has some peculiar pharmacological properties and outcome data. Here a group of experts in AF and VTE answers a set of questions on its practical use, trying to define the profile of patients that would be most appropriate for its use.

Original language	English
Pages (from-to)	1-18
Number of pages	18
Journal	Advances in Therapy
DOIs	https://doi.org/10.1007/s12325-017-0488-9
Publication status	Accepted/In press - Feb 13 2017
Externally published	Yes

Keywords

Atrial fibrillation
Edoxaban
Non-vitamin K antagonist oral anticoagulants
Oral anticoagulants
Venous thromboembolism
Vitamin K antagonists

ASJC Scopus subject areas

Medicine(all)
Pharmacology (medical)

Access to Document

10.1007/s12325-017-0488-9

Cite this

@article{06254e0ac7b84cf8bd62881f1a49f5fe,

title = "Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide",

abstract = "Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials with the vitamin K antagonist warfarin. Edoxaban has some peculiar pharmacological properties and outcome data. Here a group of experts in AF and VTE answers a set of questions on its practical use, trying to define the profile of patients that would be most appropriate for its use.",

keywords = "Atrial fibrillation, Edoxaban, Non-vitamin K antagonist oral anticoagulants, Oral anticoagulants, Venous thromboembolism, Vitamin K antagonists",

author = "Caterina, {Raffaele De} and Walter Ageno and Giuseppe Boriani and Paolo Colonna and Angelo Ghirarduzzi and Giuseppe Patti and Roberta Rossini and Andrea Rubboli and Piercarla Schinco and Giancarlo Agnelli",

year = "2017",

month = feb,

day = "13",

doi = "10.1007/s12325-017-0488-9",

language = "English",

pages = "1--18",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Springer Healthcare",

}

TY - JOUR

T1 - Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers

T2 - A Practical Guide

AU - Caterina, Raffaele De

AU - Ageno, Walter

AU - Boriani, Giuseppe

AU - Colonna, Paolo

AU - Ghirarduzzi, Angelo

AU - Patti, Giuseppe

AU - Rossini, Roberta

AU - Rubboli, Andrea

AU - Schinco, Piercarla

AU - Agnelli, Giancarlo

PY - 2017/2/13

Y1 - 2017/2/13

N2 - Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials with the vitamin K antagonist warfarin. Edoxaban has some peculiar pharmacological properties and outcome data. Here a group of experts in AF and VTE answers a set of questions on its practical use, trying to define the profile of patients that would be most appropriate for its use.

AB - Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials with the vitamin K antagonist warfarin. Edoxaban has some peculiar pharmacological properties and outcome data. Here a group of experts in AF and VTE answers a set of questions on its practical use, trying to define the profile of patients that would be most appropriate for its use.

KW - Atrial fibrillation

KW - Edoxaban

KW - Non-vitamin K antagonist oral anticoagulants

KW - Oral anticoagulants

KW - Venous thromboembolism

KW - Vitamin K antagonists

UR - http://www.scopus.com/inward/record.url?scp=85012249761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012249761&partnerID=8YFLogxK

U2 - 10.1007/s12325-017-0488-9

DO - 10.1007/s12325-017-0488-9

M3 - Article

AN - SCOPUS:85012249761

SP - 1

EP - 18

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

ER -

Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this